Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$98.82 USD

98.82
666,765

+1.62 (1.67%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 250)

Industry: Medical Services

Zacks News

HealthEquity (HQY) Surpasses Q2 Earnings Estimates, FY24 View Up

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the second quarter of fiscal 2024.

Why You Should Add Surmodics (SRDX) Stock to Your Portfolio

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Revvity (RVTY) Launches Three New Preclinical Research Systems

Revvity (RVTY) launches new preclinical imaging technologies for breakthrough discoveries. Learn how they can help advance research and boost Revvity's prospect.

Compared to Estimates, HealthEquity (HQY) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended July 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

HealthEquity (HQY) Beats Q2 Earnings and Revenue Estimates

HealthEquity (HQY) delivered earnings and revenue surprises of 12.77% and 1.95%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain PacBio (PACB) Stock for Now

PacBio's (PACB) product development activities raise optimism about the stock.

DexCom's (DXCM) G6 CGM Connects With Omnipod 5 AID in Germany

DexCom's (DXCM) G6 CGM system and Omnipod 5 AID system can now simplify diabetes management and improve health outcomes in Germany.

NextGen's (NXGN) Shares Rise on Potential Acquisition Rumors

NextGen (NXGN) and a private equity firm, Thomas Bravo, are in advanced stages of discussion related to the acquisition of the former by the latter.

Abbott's (ABT) New Positive Data Favors OCT in Stent Implantation

Abbott's (ABT) latest late-breaking data reflects OCT's potential to improve clinical practice related to stent placement.

Is HealthEquity (HQY) Outperforming Other Medical Stocks This Year?

Here is how HealthEquity (HQY) and InMode (INMD) have performed compared to their sector so far this year.

Neogen (NEOG) Launches SureKill Evolve SC Pest Management Tool

Neogen (NEOG) introduces the latest solution in the SureKill brand of products, SureKill Evolve SC.

Reasons to Add Stryker (SYK) Stock to Your Portfolio Now

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

Masimo's (MASI) Inks Agreement to Improve Patient Outcomes

Masimo's (MASI) latest deal with FMOLHS is expected to enhance patient safety and improve patient outcomes.

Veeva (VEEV) Rises on Robust Earnings: More Room to Grow?

Veeva (VEEV) reports better-than-expected earnings and revenues for the second quarter. The raised earnings outlook for fiscal 2024 reflects optimism. Will the uptrend in shares continue?

Quest Diagnostics' (DGX) AAV Test Gets FDA's Breakthrough Nod

Quest Diagnostics (DGX) achieves breakthrough designation for AAVrh74 ELISA and expands collaboration with Sarepta Therapeutics.

Cardinal Health's (CAH) Latest Launch to Enhance Neonatal Feeding

Cardinal Health's (CAH) latest offering is likely to help premature and newborn infants develop the oral coordination skills important for the faster transition to independent feeding.

Exact Sciences' (EXAS) OncoExtra Test Selected for ComboMATCH

Exact Sciences' (EXAS) Laboratory and OncoExtra test gets selected by the NCI for ComboMATCH trials.

Patterson Companies (PDCO) Q1 Earnings In Line, Sales Hurt by FX

Patterson Companies' (PDCO) first-quarter fiscal 2024 results reflect robust improvement in Dental Equipment sales, value-added services and Animal Health segment.

Catalent (CTLT) Gains Post Deal With Elliott and Earnings Report

Catalent's (CTLT) deal with Elliott and earnings report boost its shares. The company will likely improve its value and growth with the agreement and its strategic investments.

Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

STERIS (STE) Banks on New Pact for Growth Amid Rising Expenses

Continuous procedure volume growth in the United States, favorable pricing and market share gains are driving STERIS' (STE) Healthcare segment organic growth.

Haemonetics (HAE) Expands VASCADE System Portfolio in Germany

Haemonetics (HAE) announces the first treatment of patients in Germany with the VASCADE MVP Venous Vascular Closure system.

Zacks Industry Outlook Highlights Medpace, HealthEquity and Surgery Partners

Medpace, HealthEquity and Surgery Partners are part of the Zacks Industry Outlook article.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Urmimala Biswas headshot

3 Medical Services Stocks Countering Industry-Wide Headwinds

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and SGRY are set to gain the most. However, staffing shortages may disrupt the trend.